Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKCEA-APOCIII-LRx for hypertriglyceridemia inflammatory activity
NL-OMON51943Phase 2Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of olezarsen in hypertriglyceridemia (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Change in mass cytometry monocyte phenotype panel and Change in postprandial triglyceride AUC. Started Sep 2022; status: recruiting.
02
Drugs
olezarsen
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NL-OMON51943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51943.